Modeling acute myocardial infarction and cardiac fibrosis using human induced pluripotent stem cell-derived multi … – Nature.com
Posted: May 4, 2024 at 2:44 am
Derivation of HOs from hiPSCs
We previously generated hiPSC-derived cardiac organoids (COs), and the CO formation resulted in the enhanced maturity of hiPSC-derived cardiomyocytes [18]. However, these COs could not mimic the diverse cellular composition of the human heart. Thus, we refined our differentiation protocol to generate heart organoids (HOs) designed to accommodate the coexistence of various cardiac lineage cells by modulating BMP, VEGF, FGF, and TGF signaling during differentiation (Fig. 1A).
A Overall schematic diagram of differentiation from hiPSC into COs and HOs. B Comparison of beating efficiency of COs and HOs at day 830 of differentiation. C The morphology of COs and HOs for 30 days, including the differentiation period.
An assessment of organoid beating efficiency spanned the entire differentiation period from day 8 to day 30 for both COs and HOs (Fig. 1B). On day 810 of differentiation, both COs and HOs initiated discernible beating (Fig. 1B). Notably, COs showed a beating efficiency of 68.1%, whereas HOs exhibited a lower rate of 34.5% on day 8 of differentiation. However, although the beating efficiency at the beginning of differentiation was higher in COs than in HOs, HOs displayed an ascending trend in their beating rate post-differentiation initiation, culminating in a 100% beating efficiency by day 30 (Fig. 1B), and resulted in similar beating efficiency to COs on day 30 (Fig. 1C, Videos 1 and 2).
Moreover, we validated the cardiomyocyte subtypes in the organoids by confirming the expression levels of MLC-2v and MLC-2a, indicative of ventricular and atrial types of cardiomyocytes, respectively. We observed that the expression of MLC-2a initiated early in differentiation (from D5 to D10), while MLC-2v expression gradually increased over the differentiation period. At D24, the majority of cardiomyocytes in both COs and HOs exhibited strong expression of MLC-2v (Fig. S1A and B).
To assess the cellular distribution in the COs and HOs, FACS analysis was performed (Figs. 2A, B and S2). Within COs, the mean distribution of cTnT, CD90, and VE-cadherin was 92.232.62%, 6.241.55%, and 4.731.48%, respectively (Figs. 2A, B and S2). Conversely, in HOs, these distributions were determined to be 51.095.92%, 24.634.08%, and 14.033.34%, respectively (Figs. 2A, B and S2).
A Representative pie chart showing the distribution of cTnT, a cardiomyocyte (CM)-specific marker, CD90, a cardiac fibroblast (CF)-specific marker, and VE-Cad, an endothelial cell (EC)-specific marker, in CO and HO. B The graph displays the mean cellular compositions of cardiomyocytes, fibroblasts, and endothelial cells across 11 different batches of COs and HOs. C Representative z-stack image of HOs and COs using confocal microscopy (left). Staining for cTnT (green) and VE-cad (red) in 2D monolayer culture of cells dissociated from HOs and COs (right). Scale bar: 100m. D Z-stack image of co-staining for Vimentin (fibroblast marker, green), -actinin (cardiomyocyte marker, red), and DAPI (blue) in COs and HOs. Scale bar: 100m. E Comparison of the gene expression levels for various cell types in COs and HOs. Quantitative analysis of gene expression levels as performed with real-time PCR. The expression levels of cardiomyocyte markers (NKX2.5, TNNT2, MYL2, and MYL7), endothelial cell markers (CD34, PECAM1, SOX17, and FOXA2), fibroblast markers (CD90, PDGFR, Vimentin, and TCF21) normalized to that of GAPDH. Data were shown as fold-change relative to COs, as meanSD, by 2-way ANOVA (n=3). A significant difference is indicated by #p<0.05, ##p<0.01, ###p<0.001, ####p<0.0001 compared with COs and ns (non-significant).
Immunostaining was also performed to visualize the distribution of cardiac lineage cells (Fig. 2C and D). Consistently with FACS analysis, COs prominently displayed cTnT expression within the organoids, while HOs displayed VE-cadherin expression on the surface of HOs (Fig. 2C, Videos 3, 4). The distinct distribution of blood vessel cells in HOs was further verified through the culture of dissociated organoids, and the dissociated cells from HOs exhibited a composition of both cTnT-positive cells and VE-Cad-positive cells (Fig. 2C). In contrast, the dissociated cells from COs exclusively displayed cTnT-positive cells (Fig. 2C). In addition, the HOs exhibited notable expression of Vimentin, a fibroblast marker, in comparison to COs (Fig. 2D).
The differences were further validated through qPCR analysis, and this analysis substantiated that COs exhibited a relatively increased expression of NKX 2.5, a transcription factor governing heart development, in addition to TNNT2, MYL2, and MYL7 (Fig. 2E). In contrast, HOs displayed significant upregulation in genes related to cardiac fibroblasts (CD90 and PDGFR), Vimentin, and TCF21, all in comparison to COs (Fig. 2E). Furthermore, endothelial-related genes including CD34, PECAM1, SOX17, and FOXA2 exhibited elevated expression levels in HOs relative to COs (Fig. 2E).
To gain a deeper understanding of the intricate gene expression within HOs, we utilized single-cell RNA sequencing (Fig. 3). Utilizing UMAP clustering and marker identification, the pool of 2587 cells from HOs was effectively categorized into distinct groups, encompassing cardiomyocytes, fibroblasts, and endothelial cells (Fig. 3A). To compare the representative gene expression patterns by cell type in both COs and HOs, we selected genes with p-values below 0.05 and visualized their expression using violin plots. Additionally, a comparative examination of gene expression patterns between COs and HOs was presented through violin plots. Notably, representative genes linked to cardiomyocytes, such as MYL2, MYL7, MYH7, TNNC1, MYBP3, and CACNA1C, exhibited enhanced expression in COs when compared to HOs (Fig. 3B). Similarly, an analysis was also extended to endothelial cells. Endothelial-related genes such as APOLD1, GIMAP4, PECAM1, PRSS23, STC1, and VEGFC exhibited an upregulation in HOs compared to COs (Fig. 3C). Shifting the focus to cardiac fibroblasts, the violin plots highlighted genes like AGT, CLU, and HMGA1 illustrating disparities between COs and HOs (Fig. 3D).
A Uniform manifold approximation and projection (UMAP) plots of HOs. Winseurat data sets labeled with Winseurat clusters. Detailed clustering within CMs (pink), CFs (green), and ECs (purple) clusters. BD Violin plots of representative genes for CMs (MYL2, MYL7, MYH7, TNNC1, MYBPC3, and CACNA1C), ECs (APOLD1, GIMAP4, PECAM1, PRSS23, STC1, and VEGFC), and CFs (AGT, CLU, and HMGA1). These genes were selected fold-change about 2-fold, average expression about 4 or more, and p-value 0.05 or less.
Clusters where unselected genes were grouped under the unclassified category in HOs were further analyzed (Fig. 3A). To predict cell types within the populations, we made use of databases such as pangiaoDB and GeneCard. These predictions revealed that the unclassified population mainly comprised pericytes, epithelial cells, neurons, and other cell types. These findings collectively indicate that HOs possess a more comprehensive genetic repertoire of heart constituent cells in comparison to COs.
With the established HOs, we mimicked the pathological conditions of acute myocardial infarction (AMI) and subsequent cardiac fibrosis to model human heart disease (Fig. 4A). To replicate hypoxia-induced ischemic conditions, we introduced 50M of cobalt chloride (CoCl2) [19] to the organoids along with glucose-depleted culture medium. This approach effectively elevated the expression of hypoxia-inducible factor-1 (HIF-1) in both COs and HOs (Figs. 4B and S3).
A Schematic of an experiment mimicking the heart disease in organoids by ischemia-reperfusion injury mechanism that occurs in the human adult heart and followed fibrogenesis. B Expression of the HIF-1 through western blots. Quantitative analysis of HIF-1 performed using Image J software. The expression of HIF-1 normalized to that of GAPDH. Data were shown as fold-change, and a significant difference is indicated by ****, ####p<0.0001, and ns (non-significant). C Immunofluorescence images of the expression levels of apoptotic marker (cleaved caspase-3, green) and cardiomyocyte marker (cTnT, red) in COs and HOs after IR injury. The scale bar represents 100m. D Representative western blot image and quantitative analysis of cleaved caspase-3. Data normalized to that of caspase-3. Equal protein loading amounts were confirmed by GAPDH expression. The corresponding density ratio was calculated by the average intensity of the bands from Image J software. Data were shown as fold-change, and a significant difference is indicated by ****, ####p<0.0001 and ns (non-significant). E Representative image and quantitative analysis of TUNEL assay (green). Data were shown as fold-change, as meanSD, by 2-way ANOVA (n=3). Significant difference is indicated by #p<0.05, ***p<0.001, ****, ####p<0.0001 (*compared to control group; #compared to COs), and ns (non-significant). The scale bar represents 100m.
In the clinical condition, the rapid reintroduction of blood flow post-reperfusion can lead to an immediate supply of oxygen and nutrients, triggering heightened inflammation and oxidative stress, thereby potentially causing tissue damage. A study suggested that high glucose sensitizes cardiomyocytes to ischemia-reperfusion (IR) injury [20]. Another study proposed that intracellular and mitochondrial calcium overload may contribute to reperfusion injury by exacerbating oxidative stress [21]. Based on these findings, we hypothesized that these factors could mimic reperfusion injury in CoCl2-treated HOs. To test this hypothesis, we applied a culture condition in which high glucose and calcium ion levels, then CoCl2-treated COs and HOs were exposed to a reperfusion medium rich in glucose and calcium ions for 72h.
To verify the induction of apoptosis in both COs and HOs following IR injury, we performed co-staining of cTnT and cleaved caspase-3 in organoid sections (Fig. 4C). This co-staining provided confirmation of the reduction in cardiomyocytes and the increase in apoptosis were more pronounced in HOs compared to COs (Fig. 4C). Western blot analysis against the cleaved caspase-3 further confirmed the more effective induction of apoptosis in HOs relative to COs (Figs. 4D and S4). Validation of apoptosis in the IR-injured organoids was also carried out using the TUNEL assay, and the findings demonstrated the more increased apoptotic cells within the HOs than that of COs (Fig. 4E). Additionally, Western blot analysis unveiled a more substantial increase in the Bax/Bcl2 signaling in HOs compared to COs (Fig. S5).
IR injury in humans leads to the disruption of sarcomere structures and a reduction in cardiac markers, including cTnT and cTnI, within heart tissue [22]. Furthermore, in clinical practices, markers such as cTnI, Myoglobin (MB), and Creatine kinase M (CKM) are quantified in blood to diagnose myocardial infarction resulting from IR injury [23].
Consistent with previous findings, we observed a more pronounced disintegration of sarcomere structures in HOs following IR injury, in contrast to COs (Fig. 5A). Simultaneously, the intracellular expression of cTnT and cTnI showed a marked reduction in HOs compared to COs (Figs. 5B and S6). Moreover, the release of cTnI, MB, and CKM from HOs began to be released from the organoids 24h post-IR injury, with the highest levels observed at 72h and exhibited significantly higher levels than those from COs (Fig. 5C).
A Immunofluorescence images of the expression levels of sarcomeric -actinin and DAPI in the control and IR groups. White dotted line in IR-induced HOs indicates the disintegrated sarcomere structure in the organoids. The scale bar represents 100m and magnified image scale bar represents 20m. B Western blot analysis in cell lysates from COs and HOs in control and IR groups. The protein expression of cTnT and cTnI, which are essential for cardiac structure was calculated by the average intensity of the bands from Image J software. The comparison of the fold change between the COs and HOs was normalized by the control group. C Extracellular secretion levels of cTnI, myoglobin (MB), and creatine kinase M type (CKM), which AMI indicators in control and IR group during culture periods. Secretion of cTnI, MB, and CKM was measured by ELISA. All data were shown as meanSD by 2-way ANOVA (n=3). Significant difference is indicated by ***, ###p<0.001, ****, ####p<0.0001(*compared to control group; #compared to COs), and ns (non-significant).
In addition, an analysis of inflammatory responses and necrosis-related mRNA levels in both COs and HOs following IR injury revealed a more notable increase in gene expressions within HOs in comparison to COs (Fig. S7A). Furthermore, HOs subjected to IR injury displayed a more significant upregulation of NF-B, a crucial transcription factor involved in inflammation and processes related to cardiac-vascular damage, in comparison to IR-injured COs (Figs. S7B and S8). The expression levels of phosphorylated ERK, phosphorylated JNK, and phosphorylated p38, which are indicative of increased signaling pathways in cardiac remodeling post-AMI [24, 25], were also significantly elevated in IR-injured HOs compared to COs (Figs. S7C and S8).
Intracellular calcium overload and subsequent mitochondrial calcium accumulation are observed in acute myocardial ischemia, and these phenomena are exacerbated during reperfusion, ultimately leading to mitochondrial permeability transition pore (mPTP) opening [26]. Furthermore, within a physiological environment, the bulk of calcium during cycles of contraction and relaxation is released from and taken up by the sarcoplasmic reticulum (SR) [27]. Therefore, quantifying SR calcium content is essential in elucidating the pathophysiological mechanisms of calcium overload.
We first observed calcium overload in the organoids by measuring the activity of sarco/endoplasmic reticulum calcium ATPase (SERCA), which significantly influences SR calcium storage [28], to infer the SR calcium content. Before IR injury, there were no significant differences in basal and peak intracellular calcium concentrations between COs and HOs during the contractionrelaxation cycle (Fig. 6A and B). However, after IR injury, both the basal and peak calcium concentrations were significantly higher in HOs compared to COs (Fig. 6A and B). Subsequently, we measured the activity of SERCA (kSERCA) by calculating the time constant after inhibiting SERCA and observed that the SERCA activity was notably increased in IR-injured HOs compared to IR-injured COs (Fig. 6C). In the same context, the phosphorylated phospholamban (PLN) expression was significantly elevated in IR-injured HOs, confirming the accelerated SERCA activity (Fig. 6D and S9). This suggests that SERCA activity preferentially increases during IR induction in HOs, leading to a significant increase in SR calcium storage in IR-injured HOs compared to IR-injured COs.
A Representative trace of calcium transient in COs and HOs before and after IR injury. control and IR groups. B Basal and peak Ca2+ concentrations were measured using calcium imaging. All data were shown as meanSD by 2-way ANOVA (n=1820). A significant difference in all graphs are indicated by *, #p<0.05, **, ##p<0.01, ***, ###p<0.001, ****, ####p<0.0001 (*compared to control group; #compared to COs), and ns (non-significant). C The SERCA rate constant, reflecting the activity of SERCA, was calculated by subtracting the reciprocal of the time constant measured after inhibiting SERCA from the reciprocal of the time constant measured in the transient. All data were shown as meanSD by 2-way ANOVA (n=1820). A significant difference in all graphs are indicated by *, #p<0.05, **, ##p<0.01, ***, ###p<0.001, ****, ####p<0.0001 (*compared to control group; #compared to COs), and ns (non-significant). D Western blot analysis of phospholamban and phosphorylated phospholamban in COs and HOs before and after IR injury. Quantitative analysis of all western blot data was calculated by the average intensity of the bands in Image J software. Equal protein loading amounts of western blot data were confirmed by GAPDH expression. A significant difference of all graphs is indicated by #,*p<0.05, ##,**p<0.01 ###,***p<0.001, ####,****p<0.0001(*Compared to control group; #compared to COs), and ns (non-significant). E Representative immunofluorescence images of MPTP opening (calcein, green) in control and IR groups. The scale bar represents 200m. F MPTP opening (calcein) ratio in each group was calculated by image J software. This data was normalized to the control of COs. G Beating characteristics of COs and HOs in IR and control groups. Beating analysis was performed by monitoring calcium fluorescence over a period of 20s under control and IR conditions. A comparison of BPM (beat per minute), peak-to-peak duration, and time-to-peak was performed on COs and HOs in each group. All data were shown as meanSD by 2-way ANOVA (n=3). A significant difference in all graphs is indicated by **, ##p<0.01, ***, ###p<0.001, ****, ####p<0.0001 (*compared to the control group; #compared to COs), and ns (non-significant). H Schematic summary of findings in (AF).
To determine whether the IR condition facilitates mPTP opening in HOs, we directly measured fluorescence intensity using an mPTP assay kit in the IR-injured organoids and found a more significant reduction in fluorescence intensity within IR-injured HOs compared to COs (Fig. 6E and F), suggesting that IR injury in HOs leads to a greater increase in mPTP opening than IR injury in COs.
Moreover, the real-time calcium transient assay allowed for an analysis of calcium handling properties in IR-injured organoids (Figs. 6G and S10). Amplitudes showed no significant difference between COs and HOs during ischemia and IR injury (Fig. 6G). However, HOs subjected to ischemia-injury exhibited aberrant beating properties (Fig. 6G) with a significant change in beating rate (peak-to-peak) and systolic time (time-to-peak), indicated a disease-like model. Consistent with the ischemia results, the IR-injury condition induced further detrimental calcium handling properties in HOs, resulting in a decrease in beating and systolic parameters compared to those of COs (Fig. 6G). Collectively, these results indicate that multicellular HOs effectively mimic clinically observed AMI pathologies, such as calcium overload and mPTP opening under IR conditions, as well as the mimicking defects in calcium handling function (Fig. 6H).
Cardiac fibrosis is a consequential outcome of cardiac remodeling following AMI [29]. To replicate the cardiac fibrosis within IR-injured HOs, we cultured the organoids with 10M TGF-1 for 7 days. Staining for COL1A1, a marker indicating fibrosis progression, revealed a more pronounced accumulation of collagen in IR-injured HOs after fibrosis induction compared to IR-injured COs (Fig. 7A and S12A). This substantial collagen accumulation in IR-injured HOs was further confirmed through western blot analysis and Massons trichrome (MT) staining (Fig. 7B, C and S12B). Additionally, we assessed increased expression levels of mRNA associated with fibrosis-related genes (ACTA2, POSTN, Vimentin, MMP2) and collagen-related genes (PAI1, COL1A1, COL1A2, COL3A1) in IR-injured HOs after fibrosis induction using quantitative PCR (Fig. S12C).
A Representative immunofluorescence images of COL1A1 (green) and DAPI (blue) in each group. The scale bar represents 100m. B The protein expression of COL1A1 and -SMA, which are fibroblast activation and fibrosis indicators using western blot in cell lysates from COs and HOs in each group. Equal protein loading amounts were confirmed by GAPDH expression. C The morphologies of the IR-Fibrosis organoid by Massons Trichrome staining. The scale bar represents 40m. D Evaluation of the electrophysiological function of COs and HOs on the electrode of the MEA plate in each group. Magnified image to show a heatmap of a representative MEA recording. The spike activity of each active electrode is color-coded: white/red represents high spike activity; blue/black represents low spike activity. E Beating rate (BPM), Spike amplitude, FPDcF, and conduction velocity of COs and HOs in each group through MEA recording. All data were shown as fold-change, as meanSD, by 2-way ANOVA (n=3). A significant difference of all graphs is indicated by #,*p<0.05, ##,**p<0.01, ###,***p<0.001, ####,****p<0.0001(*Compared to control group; #compared to COs) and ns (non-significant). F Comparison of contraction in control COs versus IR-fibrosis COs and control HOs versus IR-fibrosis HOs.
To validate the alterations in calcium handling in HOs under the IR-fibrosis condition, we conducted a calcium transient assay. Real-time video recordings allowed for an analysis of beating properties (Fig. S13A and Videos 11, 12) of the organoids, and HOs subjected to IR-fibrosis displayed an increase in amplitude and beating (peak-to-peak) but a decrease in systolic (time-to-peak) compared to IR-fibrosis COs (Fig. S13B), reflecting a form of arrhythmic event in the human heart.
Heart disease also leads to alterations in electrophysiological properties [30, 31]. To demonstrate the defect of electrophysiological characteristics in IR-fibrosis HOs, multielectrode arrays (MEA) were utilized (Fig. 7D). Consistent with the analysis of beating properties in calcium transient, the beating rate (BPM) was significantly increased in IR-fibrosis HOs compared to IR-fibrosis COs, and the BPM exceeded 100, a characteristic of tachycardia (Fig. 7E). The spike amplitude, indicative of action potential height, demonstrated a decline in both COs and HOs within the IR-fibrosis group, but HOs displayed a particularly significant difference compared to COs (Fig. 7E). Measurement of the field potential duration corrected by Fridericias formula (FPDcF) unveiled a twofold increase in HOs subjected to IR-fibrosis (Fig. 7E), mirroring the prolongation of the period between the onset of the Q wave and the conclusion of the T wave. The cardiac conduction velocity exhibited a significant slowing in IR-fibrosis HOs compared to IR-fibrosis COs, resulting from an elevated risk of re-entrant excitation attributing to collagen accumulation in HOs (Fig. 7E). Additionally, induction of fibrosis subsequent to IR injury resulted in reduced contractility of COs but maintained normal cardiac rhythms, whereas, in HOs, it led to both diminished contractility and irregular cardiac rhythms (Fig. 7F).
The QuantSeq 3 mRNA-Sequencing analysis provided further support for the modeling of AMI and cardiac fibrosis in HOs (Fig. 8). In comparing the up-regulated KEGG pathways between control HOs and IR-injured HOs (Fig. 8A), it was observed that the FoxO signaling pathway, known to be activated in cardiomyocytes under ischemic stress [32], was predominantly up-regulated. Additionally, pathways associated with cancer, which share common systemic pathology and mechanisms with heart failure [33], were also up-regulated in IR-injured HOs. Furthermore, pathways related to extracellular matrix (ECM)-receptor interaction, PI3K-Akt signaling, and HIF-1 signaling were up-regulated in IR-injured HOs compared to control HOs which are known to play crucial roles in cardiac remodeling [34], alleviating negative post-infarct changes in myocardium [35], and modulating post-infarct healing after myocardial ischemic injury [36], respectively. Interestingly, pathways associated with human papillomavirus, insulin resistance, efferocytosis, longevity genes, and focal adhesion kinase (FAK) inhibition were also found to be up-regulated in IR-injured HOs. These pathways are implicated in various processes such as the diagnosis of myocardial infarction [37], hypoxia-induced inhibition of angiogenesis [38], macrophage-mediated clearance of dead cells during myocardial infarction [39], modulation of cardiovascular function [40], and regulation of cardiac fibrosis post-MI [41].
A Visualized graphs of up-regulated KEGG pathways in IR-injured HOs compared to control HOs. B Visualized graphs of up-regulated KEGG pathways in IR-fibrosis HOs compared to control HOs. The pathways were selected based on criteria including a fold change >2 and a p-value less than 0.05.
The comparison between control HOs and IR-fibrosis HOs revealed up-regulated pathways associated with cardiac fibrosis (Fig. 8B). One of the pathways identified as up-regulated in IR-fibrosis HOs, is the calcium signaling pathway, known to play a role in fibroblast activation by increasing intracellular calcium concentration, promoting fibroblast proliferation and migration, and inducing the synthesis of extracellular matrix proteins [42]. Extracellular matrix (ECM) remodeling is closely linked to cardiac remodeling and the development of heart failure [43]. Furthermore, the renin-angiotensin-aldosterone system (RAAS) pathway, Wnt signaling pathway, and adrenergic signaling pathway were also identified as up-regulated in IR-fibrosis HOs. These pathways are known to promote myocardial fibrosis and cardiac remodeling, contributing to the progression of heart failure [44,45,46,47], respectively. Additionally, conditions such as Cushing syndrome, circadian disruption, and cardiomyopathy, which are associated with increased myocardial fibrosis [48,49,50], were found to be relevant to the up-regulated pathways in IR-fibrosis HOs. Cortisol is also experimentally shown to induce cardiomyocyte hypertrophy [51].
See the rest here:
Modeling acute myocardial infarction and cardiac fibrosis using human induced pluripotent stem cell-derived multi ... - Nature.com
- The Beating Heart (Cardiac) Cells [Last Updated On: June 24th, 2011] [Originally Added On: June 24th, 2011]
- cellalign [Last Updated On: June 24th, 2011] [Originally Added On: June 24th, 2011]
- Okamoto placenta-derived cardiomyocytes [Last Updated On: June 25th, 2011] [Originally Added On: June 25th, 2011]
- Cardiac Stem Cell Therapy [Last Updated On: June 26th, 2011] [Originally Added On: June 26th, 2011]
- Wow! UW Research labs [Last Updated On: June 26th, 2011] [Originally Added On: June 26th, 2011]
- Cardiac Stem Cell Therapy [Last Updated On: June 28th, 2011] [Originally Added On: June 28th, 2011]
- cellalign [Last Updated On: July 3rd, 2011] [Originally Added On: July 3rd, 2011]
- Insidermedicine In 60 - August 4, 2011 [Last Updated On: August 25th, 2011] [Originally Added On: August 25th, 2011]
- Cardiac Stem Cells in End-Stage Human Failing Hearts: Are they functional? [Last Updated On: August 28th, 2011] [Originally Added On: August 28th, 2011]
- Did you have a Heart Attack and Need to Recover your Cardiac Muscle? [Last Updated On: September 5th, 2011] [Originally Added On: September 5th, 2011]
- Heart repair using own stem cells after heart attack: Future Health keynote speaker [Last Updated On: September 5th, 2011] [Originally Added On: September 5th, 2011]
- Cardiac Stem Cell Therapy at Rostock University [Last Updated On: September 5th, 2011] [Originally Added On: September 5th, 2011]
- Cardiovascular Therapies: Spotlight on Stem Cell Research - Douglas Boyd [Last Updated On: September 5th, 2011] [Originally Added On: September 5th, 2011]
- Davos Question: Stem Cell Answer [Last Updated On: September 5th, 2011] [Originally Added On: September 5th, 2011]
- Stem Cell operation in Cardiac Surgery-Al-Jazeerah [Last Updated On: September 6th, 2011] [Originally Added On: September 6th, 2011]
- Stem Cell Therapy in Cardiac Disease [Last Updated On: September 6th, 2011] [Originally Added On: September 6th, 2011]
- Designer Life: repair brain, heart with stem cells - Future Health keynote speaker [Last Updated On: September 7th, 2011] [Originally Added On: September 7th, 2011]
- Stem Cells: Mending a broken heart? [Last Updated On: September 7th, 2011] [Originally Added On: September 7th, 2011]
- Cardiac Stem Cells in End-Stage Human Failing Hearts: Are they functional? [Last Updated On: September 8th, 2011] [Originally Added On: September 8th, 2011]
- Oral Surgeon utilizes StemSave to preserve stem cells in wisdom teeth to combat cardiac disease [Last Updated On: September 9th, 2011] [Originally Added On: September 9th, 2011]
- Cardiac Recovery Points to Adult Stem Cells [Last Updated On: September 9th, 2011] [Originally Added On: September 9th, 2011]
- Oral Surgeon utilizes StemSave to preserve stem cells in wisdom teeth to combat cardiac disease [Last Updated On: September 10th, 2011] [Originally Added On: September 10th, 2011]
- Stem Cell operation in Cardiac Surgery-Al-Jazeerah [Last Updated On: September 10th, 2011] [Originally Added On: September 10th, 2011]
- Cardiovascular Derivatives of Embryonic Stem Cells in Cardiac Repair and Drug Discovery [Last Updated On: September 10th, 2011] [Originally Added On: September 10th, 2011]
- Stem Cell Therapy in Cardiac Disease [Last Updated On: September 11th, 2011] [Originally Added On: September 11th, 2011]
- Cardiovascular Derivatives of Embryonic Stem Cells in Cardiac Repair and Drug Discovery [Last Updated On: September 12th, 2011] [Originally Added On: September 12th, 2011]
- Stem Cells and Cardiac Regeneration [Last Updated On: September 12th, 2011] [Originally Added On: September 12th, 2011]
- Cardiomyogenic differentiation of Mesenchymal Stem cells (KUM2/9-15c) [Last Updated On: September 12th, 2011] [Originally Added On: September 12th, 2011]
- Mark Mercola: Differentiating embryonic stem cells into adult tissues [Last Updated On: September 15th, 2011] [Originally Added On: September 15th, 2011]
- Cardiovascular Therapies: Spotlight on Stem Cell Research - Douglas Boyd [Last Updated On: September 20th, 2011] [Originally Added On: September 20th, 2011]
- Stem Cell #8 Vas Cath Removal 04/28/11 [Last Updated On: September 20th, 2011] [Originally Added On: September 20th, 2011]
- Adult Stem Cells Used To Rebuild Heart Tissue Video. More at http://www.stemcellfusion.com [Last Updated On: September 20th, 2011] [Originally Added On: September 20th, 2011]
- Stem Cell Therapy and Stem Cell Treatment with Dell [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- First US Patient In Stem Cell Transplant [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- Stem Cell Heart Surgery must see [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- Beating cardiac myocytes from differentiated mouse iPSC. [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- heart cell generation from human ES and iPS cells (embryonic and induced pluripotent stem cells).flv [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- Advanced Cell Technology OneMedForum 2011 [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- 20100804_axiogenesis.wmv [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- Pt. 1--Dr. Ali Denktas--Stem Cells as Markers after Myocardial Infarctions [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- Cardiac Tissue Can Regenerate [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- Adult Stem Cell [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- Beating cardiomyocyte monolayer [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- Valentine's Day Stem Cell Wish: Mending Broken Hearts [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- Cardiomyocytes derived from mouse Embryonic stem cells [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- UCD Med Student Receives Fulbright Award [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- Mouse GEN cells overexpressing Csx/Nkx2.5 and GATA4 behave like transient amplifying cells [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- 2010 - 2011 UConn Highlight Reel [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- William F. Testimonial of Treatment Stem Cell [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- BeatingCM_on_MEA.wmv [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- Breakthrough in Stem cell technology [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- stem cell derived cardiomyocytes [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- Mark Mercola: Differentiating embryonic stem cells into adult tissues [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- Cadiomyogenesis of human mesenchymal stem cells [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- Adult Stem Cell vs Embryonic Stem Cell Research Ethics Video [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- Heart Failure Patient After Adult Stem Cell Therapy [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- Affordable Stem Cell Therapy in Guatemala (2hrs from Miami) [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- Kevin's 2 Heart Transplants and Stem Cell Transplant [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- Immune Control of Stem Cell Mobilization [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- Patel Stem Cell Heart Failure [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- Better Drugs Through Stem Cells [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- Heart Disease Patient Describes His Stem Cell Treatment [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- Turning Adult Stem Cells into Medicine - Zannos Grekos, MD [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- Cardiomyocytic differentiation of endometrial stem cells. [Last Updated On: September 26th, 2011] [Originally Added On: September 26th, 2011]
- Turning Adult Stem Cells into Medicine - Zannos Grekos, MD [Last Updated On: September 26th, 2011] [Originally Added On: September 26th, 2011]
- Stem Cells: Heart cells grown from mouse stem cells [Last Updated On: September 26th, 2011] [Originally Added On: September 26th, 2011]
- Beating cells [Last Updated On: September 28th, 2011] [Originally Added On: September 28th, 2011]
- Repairing Damaged Hearts with Stem Cells [Last Updated On: September 28th, 2011] [Originally Added On: September 28th, 2011]
- Heart cells grown from human embryonic stem cells [Last Updated On: September 28th, 2011] [Originally Added On: September 28th, 2011]
- CytoTune iPSCs - Cardiomyocytes [Last Updated On: September 29th, 2011] [Originally Added On: September 29th, 2011]
- Becoming Bionic: The Little Book of Hope for Heart Patients Runblog ("Dress the Part") [Last Updated On: September 29th, 2011] [Originally Added On: September 29th, 2011]
- H9 Cardiac EBs.mov [Last Updated On: September 29th, 2011] [Originally Added On: September 29th, 2011]
- Beating Cardiomyocytes from E14 Cells [Last Updated On: September 29th, 2011] [Originally Added On: September 29th, 2011]
- Human 2.0: The Helix of Our Future [Last Updated On: September 30th, 2011] [Originally Added On: September 30th, 2011]
- Beating Human Heart Cells from Embryonic Stem Cells [Last Updated On: October 1st, 2011] [Originally Added On: October 1st, 2011]
- Be still my beating stem cell heart [Last Updated On: October 1st, 2011] [Originally Added On: October 1st, 2011]
- Doctors To Use 'Trained' Stem Cells To Heal Heart [Last Updated On: October 2nd, 2011] [Originally Added On: October 2nd, 2011]
- Spontaneously and rhythmically beating engineered human heart tissue from pluripotent stem cells [Last Updated On: October 3rd, 2011] [Originally Added On: October 3rd, 2011]
- Cardiac Stem Cell Therapy - How it works [Last Updated On: October 4th, 2011] [Originally Added On: October 4th, 2011]
- Doctors To Use 'Trained' Stem Cells To Heal Heart [Last Updated On: October 4th, 2011] [Originally Added On: October 4th, 2011]